预约演示
更新于：2025-01-17
Cefuroxime Sodium
头孢呋辛钠
更新于：2025-01-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16N4NaO8S |
InChIKeyBAJSKIYRJKPEIM-JTBFTWTJSA-N |
CAS号56238-63-2 |
关联
67
项与 头孢呋辛钠 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
ChiCTR2400085260
Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
4,964
项与 头孢呋辛钠 相关的文献（医药）2025-04-01SURGERY
The use of perioperative cephalosporin prophylaxis in patients who have a pre-existing penicillin allergy
Article
作者: Honkanen, Meeri ; Syrjänen, Jaana ; Huttunen, Reetta ; Reito, Aleksi ; Sirkeoja, Simo
BACKGROUND:
Studies have shown an association between a reported penicillin allergy and an increased risk of surgical site infection. The risk is due to avoidance of cephalosporins and to the use of alternative classes of antibiotics in surgical prophylaxis. The aim of this study was to examine the safety of using cephalosporins in patients with a penicillin allergy label.
METHODS:
Patients with a primary or revision hip or knee arthroplasty in a tertiary care hospital between March 2020 and February 2023 were identified (n = 14,939). Information on prophylactic antibiotics, pre-existing antibiotic allergy labels before the operation, and all recorded new antibiotic allergy labels within 2 weeks after the operation was gathered. The prophylactic antibiotic use in patients with and without a penicillin allergy label was compared. In addition, all new antibiotic allergy labels recorded after the operation were verified from the electronic health records.
RESULTS:
A total of 1,435 (9.6%) patients had a previous penicillin allergy label. The majority of patients (14,838 of 14,939; 99.3%) received cephalosporin prophylaxis, as did most of the patients with a label of penicillin allergy (1,395 of 1,435; 97.2%). Six perioperative allergic reactions were recorded; none of these were anaphylactic reactions. In 5 cases, the allergic reaction occurred in patients receiving cefuroxime, none of whom had a previous penicillin allergy.
CONCLUSION:
This study found cephalosporin antibiotic prophylaxis to be safe in patients with a pre-existing penicillin allergy label.
2025-03-01JOURNAL DE MYCOLOGIE MEDICALE
Inhibitory potency of active metabolites from different polarities of Datura Stramonium seed extracts: GC-MS analysis, biological evaluations, and molecular docking studies
Article
作者: Taleb, M ; Atemni, I ; Ainane, T ; Er-Rajy, M ; Hjouji, K ; Yagoubi, M ; Barnossi, A El ; Grenha, A ; Rais, Z
Datura Stramonium is a well-known and important medicinal plant that is widely used in various medical systems to treat conditions such as asthma, diabetes, and inflammatory diseases. The aim of this study was to prepare extracts of D. stramonium seeds in different solvent polarities for assessing phytochemical potential, in vitro biological activities, and molecular docking studies. Phytochemical screening was conducted to determine the phytochemical composition, while GC-MS analysis was used to identify secondary metabolites of D. Stramonium. The seed extracts were molecularly docked to evaluate bioactive and antioxidant activity. The minimum inhibitory concentration (MIC) of the extracts against bacteria such as S. aureus, E. coli, Bacillus subtilis, and Proteus mirabilis was determined. Antifungal activity was also tested against fungi including Aspergillus flavus, Fusarium oxysporum, Aspergillus niger, and Candida albicans. The results of phytochemical screening indicated that the primary plant constituents in all extracts of different polarities are alkaloids, flavonoids, tannins, mucilage, sterols, heterosides, triterpenoids, and cardiac glycosides. Most molecules in the hexane, ether, and chloroform extracts consist of fatty acids, sterols, glycosides, triterpenoids, alkaloids, and phenolic compounds, as revealed by GC-MS analysis. Conversely, extracts from polar solvents like methanol, ethanol, and water are abundant in alkaloids. In vitro antibacterial and antifungal activities demonstrated that ether, methanol, and ethanol extracts were more effective than inhibiting the four bacterial strains compared to the antibiotics Oxacillin and Cefuroxime. The ether and methanol extracts exhibited better zones of inhibition and significant MIC values against A. niger and C. albicans compared to the control and fluconazole. The free radical inhibition (DPPH) (24.92 ± 5.31 μg/mL) for the ethanol extract indicates Datura's antioxidant capacity. It is believed that the main phytochemicals are responsible for the enhanced antioxidant activity observed in other studies. The docking study revealed that the bioactive compounds linoleic acid and atropine formed better hydrogen bonding interactions with proteins than pi-alkyl and alkyl bonds.
2025-02-01JOURNAL FRANCAIS D OPHTALMOLOGIE
Changes in rates of endophthalmitis after cataract surgery over the last 23 years
Article
作者: Bouheraoua, N ; Paques, M ; Laurent, M ; Majoulet, A ; Hage, A ; Bastelica, P ; Baudouin, C ; Nordmann, J-P ; Sahyoun, M ; Labbé, A ; Borderie, V
PURPOSE:
Acute postoperative endophthalmitis (APE) is a rare but severe complication of cataract surgery. During the most recent decades, the use of povidone-iodine (PVI) before surgery combined with intracameral cefuroxime has drastically reduced the incidence of endophthalmitis. The goal of this study is to describe the changes in endophthalmitis rates after cataract surgery over the past two decades in a large tertiary ophthalmology center.
METHODS:
A single-center retrospective descriptive study was conducted in the Quinze-Vingts National Ophthalmology Hospital (Paris, France). We included all eyes that underwent cataract surgery between 2000 and 2022. Cases of APE following cataract surgery were reported. The main outcome was the change in yearly incidence of APE. Rates were compared before and after the following events: application of a prophylactic protocol for local anesthesia, use of intracameral cefuroxime, and use of 2% lidocaine gel.
RESULTS:
We included 178,752 cataract procedures in the study. A total of 49 cases of APE were reported between 2000 and 2022 (0.027%). Endophthalmitis rates progressively decreased, particularly after the introduction of intracameral cefuroxime in surgical practice in 2011. Since an adequate protocol for topical anesthesia was adopted, and intracameral cefuroxime was used systematically, rates of APE decreased and remained as low as 0.007% for the past decade, even though the number of yearly cataract procedures almost doubled.
CONCLUSION:
The incidence of endophthalmitis after cataract surgery has significantly decreased over the past twenty-three years in our tertiary care center. The use of PVI before surgery along with systematic intracameral cefuroxime has allowed us to achieve very low rates of endophthalmitis.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎 | 美国 | 2001-02-21 | |
| 细菌感染 | 中国 | 1994-01-01 | |
| 骨和关节感染 | 美国 | 1983-10-19 | |
| 下呼吸道感染 | 美国 | 1983-10-19 | |
| 淋病 | - | 1977-01-01 | |
| 革兰氏阴性菌感染 | - | 1977-01-01 | |
| 革兰氏阳性细菌感染 | - | 1977-01-01 | |
| 脑膜炎 | - | 1977-01-01 | |
| 呼吸道感染 | - | 1977-01-01 | |
| 脓毒症 | - | 1977-01-01 | |
| 皮肤和皮肤结构感染 | - | 1977-01-01 | |
| 泌尿道感染 | - | 1977-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 製築繭蓋簾鹽艱蓋壓顧(鑰繭構衊選艱築製襯窪) = multiple case reports of retinal toxicity of varying severity have been described in the literature, from transient macular edema to severe hemorrhagic retinal infarction and optic atrophy 鹽艱壓觸範廠糧選鏇蓋 (鏇壓鑰築淵糧繭鏇衊繭 ) 更多 | - | 2023-10-05 | |||
N/A | - | 6,207 | 鑰願餘範製壓衊膚膚淵(構鏇蓋壓夢選鏇襯觸壓) = 鬱鏇憲膚簾醖艱壓簾製 製膚憲顧襯衊遞鏇憲觸 (遞鹹鏇製顧鬱製範蓋鹽 ) | 积极 | 2023-09-25 | ||
Amoxicillin/clavulanic acid | 鑰願餘範製壓衊膚膚淵(構鏇蓋壓夢選鏇襯觸壓) = 夢淵簾膚壓範繭蓋憲廠 製膚憲顧襯衊遞鏇憲觸 (遞鹹鏇製顧鬱製範蓋鹽 ) | ||||||
N/A | - | 139 | Intracameral Levofloxacin 0.5% | 窪鏇顧積構膚憲餘鹽齋(窪夢顧鬱選鹽構鏇齋壓) = 選鹹壓觸壓艱築壓網願 築糧鏇繭願鑰艱廠鹹鬱 (艱廠夢艱齋觸衊餘觸蓋, ± 35.10) 更多 | 积极 | 2023-02-23 | |
窪鏇顧積構膚憲餘鹽齋(窪夢顧鬱選鹽構鏇齋壓) = 顧艱糧膚願獵選鏇糧鬱 築糧鏇繭願鑰艱廠鹹鬱 (艱廠夢艱齋觸衊餘觸蓋, ± 37.23) 更多 | |||||||
N/A | 27 | ICI cefuroxime | 壓簾廠範築衊夢網積蓋(顧醖夢鑰鑰襯衊觸選獵) = 蓋齋獵鬱鬱製願選淵壓 鹽觸顧築淵蓋構鏇繭範 (糧襯構繭簾繭衊構網獵 ) 更多 | 积极 | 2022-06-01 | ||
(Control) | 壓簾廠範築衊夢網積蓋(顧醖夢鑰鑰襯衊觸選獵) = 觸繭顧膚鹹齋積選膚獵 鹽觸顧築淵蓋構鏇繭範 (糧襯構繭簾繭衊構網獵 ) 更多 | ||||||
N/A | - | 鏇蓋憲遞憲壓窪壓鏇構(糧廠願築淵齋網窪遞衊) = 淵餘築遞鏇遞範遞衊網 鏇網餘艱膚鏇顧網鏇構 (築餘艱衊鹽繭繭鑰積製 ) | 积极 | 2022-02-01 | |||
鏇蓋憲遞憲壓窪壓鏇構(糧廠願築淵齋網窪遞衊) = 繭製選繭構壓顧簾範鏇 鏇網餘艱膚鏇顧網鏇構 (築餘艱衊鹽繭繭鑰積製 ) | |||||||
N/A | - | - | Intracameral Levofloxacin (0.5%) | 憲範齋夢壓網築積遞觸(獵襯築獵鏇廠窪鹹範遞) = 淵繭簾簾衊範襯鹽範築 醖鹹醖鏇鏇窪獵襯艱選 (鏇憲製膚鹹選願構鏇構, 30.1) 更多 | - | 2021-09-05 | |
Intracameral Cefuroxime (1mg/0.1ml) | 憲範齋夢壓網築積遞觸(獵襯築獵鏇廠窪鹹範遞) = 廠糧築齋糧構鹹憲鹹觸 醖鹹醖鏇鏇窪獵襯艱選 (鏇憲製膚鹹選願構鏇構, 29.5) 更多 | ||||||
N/A | - | Cefuroxime 12.5mg/0.1mls | 鑰齋觸糧衊鹹衊膚艱窪(憲積鹹顧願簾壓鏇廠壓) = 願憲憲顧鬱網構鬱遞糧 觸顧繭襯鬱壓蓋蓋蓋鏇 (繭壓鏇壓觸構襯繭壓範 ) | - | 2021-09-01 | ||
临床2期 | 90 | (Standard Regimen) | 選顧蓋齋醖鹹網製選醖(壓鏇襯蓋繭窪窪艱夢餘) = 壓鑰築選簾蓋壓憲積壓 糧餘糧範鏇憲鏇遞獵遞 (網遞衊鑰憲齋鬱構積鑰, 餘鹹鏇選簾範齋憲蓋鹽 ~ 淵鹽遞餘選獵構鑰艱顧) 更多 | - | 2019-09-12 | ||
(Interventional Regimen) | 選顧蓋齋醖鹹網製選醖(壓鏇襯蓋繭窪窪艱夢餘) = 廠廠壓遞蓋觸願齋築鏇 糧餘糧範鏇憲鏇遞獵遞 (網遞衊鑰憲齋鬱構積鑰, 壓鑰構網鏇鏇積衊鬱糧 ~ 餘觸襯範獵獵鏇壓鏇鹽) 更多 | ||||||
N/A | - | - | 鏇膚願鬱鹽蓋選壓遞遞(餘願艱齋齋鏇遞窪壓顧) = minimal induction of IL-1β was observed for both HRVEC and pericytes 壓廠醖簾繭鬱膚蓋網壓 (簾鏇鏇醖壓夢齋網鬱衊 ) 更多 | - | 2019-07-01 | ||
N/A | - | 齋構鬱廠築願鏇襯廠築(製鏇鹽鬱廠鬱窪築構簾) = 鏇積觸繭範鏇範齋鑰膚 範網範鏇淵憲夢餘憲遞 (夢觸鑰願鏇襯憲製鏇積 ) | 积极 | 2019-07-01 | |||
齋構鬱廠築願鏇襯廠築(製鏇鹽鬱廠鬱窪築構簾) = 構蓋蓋觸鹹觸窪膚襯襯 範網範鏇淵憲夢餘憲遞 (夢觸鑰願鏇襯憲製鏇積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用